Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer
Authors:
- 7 April 2006
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (6) , 968-973
Abstract
Background: A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer. However, recent concerns about safety and convenience have prompted the development of new oral fluoropyrimidine derivatives and improved regimens. This phase II study evaluated the efficacy and safety of the oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced or recurrent colorectal cancer. Patients and methods: Forty eligible patients with histologically confirmed colorectal adenocarcinoma received this treatment. S-1 was administered orally on days 1 to 14 of a 21-day cycle. Patients were assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA < 1.25 m2), 50 mg (BSA ≥ 1.25 to < 1.50 m2), or 60 mg (BSA ≥ 1.50 m2). Irinotecan (150 mg/m2) was administered by intravenous infusion on day 1. Results: A total of 327 courses of treatment were administered to 40 patients. Five patients had complete responses, and 20 had partial responses. The overall response rate was 62.5% (95% confidential interval, 47.5%–77.5%). Median progression-free survival was 8.0 months (95% confidential interval, 5.2–11.4 months). The rates of grade 3 or 4 toxicity were as follows: neutropenia, 15%; anemia, 7.5%; anorexia, 12.5%; and diarrhea, 7.5%. Conclusions: Combined treatment with S-1 and irinotecan is an effective, well tolerated, and convenient regimen in patients with advanced colorectal cancer. Our findings suggest that combined treatment with S-1 and irinotecan is a promising regimen, offering benefits in terms of safety and survival as compared with conventional regimens in patients with advanced colorectal cancer.Keywords
This publication has 22 references indexed in Scilit:
- New options and old dilemmas in the treatment of patients with advanced colorectal cancerAnnals of Oncology, 2004
- Phase II study of oral S‐1 for treatment of metastatic colorectal carcinomaCancer, 2004
- Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent PanelJournal of Clinical Oncology, 2001
- Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal CancerNew England Journal of Medicine, 2001
- Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2000
- Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinomaBritish Journal of Cancer, 2000
- An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal CancersOncology, 1999
- Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.Journal of Clinical Oncology, 1998
- Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in ratsCancer Chemotherapy and Pharmacology, 1996
- The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathyCancer, 1993